ValoreQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSpese di vendita, generali e amministrative1.52 B1.45 B1.5 B1.51 B1.53 B6 BRicerca e sviluppo106 M84 M91 M94 M98 M367 MReddito operativo483 M767 M692 M629 M535 M2.62 BProventi non operativi, Totale-42 M0-10 M-10 M-10 M-30 MOneri finanziari, al netto degli interessi capitalizzati108 M106 M107 M107 M109 M429 MProventi non operativi, esclusi gli oneri finanziari-45 M-106 M-118 M-127 M-118 M-469 MEntrate/uscite straordinarie3 M01 M10 M-1 M—Utile al lordo delle imposte346 M672 M588 M526 M427 M2.21 BQuota di utile——————Imposte53 M198 M168 M128 M97 M591 MInteressi di minoranza——————Altri proventi/oneri al netto delle imposte-33 M-18 M-17 M-21 M-13 M-69 MUtile netto al lordo delle attività cessate293 M474 M420 M398 M330 M1.62 BAttività cessate——————Utile netto293 M474 M420 M398 M330 M1.62 BRegolazione della diluizione——————Dividendi privilegiati——————Utile netto diluito attribuibile agli azionisti ordinari293 M474 M420 M398 M330 M1.62 BUtile base per azione (EPS base)0.160.250.220.210.170.85Utile diluito per azione (EPS diluito)0.160.250.220.210.160.84Numero medio di azioni ordinarie in circolazione1.92 B1.92 B1.92 B1.92 B1.92 B—Azioni diluite in circolazione1.92 B1.92 B1.93 B1.92 B1.92 B—EBITDA79 M703 M594 M529 M-6 M1.82 BEBIT-83 M560 M452 M388 M-144 M1.26 BCosto del fatturato1.59 B1.61 B1.58 B1.54 B1.64 B6.37 BAltri costi del venduto——————Ammortamento e svalutazione (liquidità)150 M143 M142 M141 M138 M564 M
Kenvue Inc. Common Stock
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.
Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index.
CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO.